175 related articles for article (PubMed ID: 36447058)
1. A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly.
Fleseriu M; Zhang Z; Hanman K; Haria K; Houchard A; Khawaja S; Ribeiro-Oliveira A; Gadelha M
Pituitary; 2023 Feb; 26(1):9-41. PubMed ID: 36447058
[TBL] [Abstract][Full Text] [Related]
2. Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study.
Neggers SJ; Pronin V; Balcere I; Lee MK; Rozhinskaya L; Bronstein MD; Gadelha MR; Maisonobe P; Sert C; van der Lely AJ;
Eur J Endocrinol; 2015 Sep; 173(3):313-23. PubMed ID: 26047625
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study.
Colao A; Zgliczyński W; Komorowski J; Kos-Kudła B; Tabarin A; Kerlan V; Minuto FM; Scaroni C; Bolanowski M
Endokrynol Pol; 2019; 70(4):305-312. PubMed ID: 31274183
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological management of acromegaly: a current perspective.
Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
[TBL] [Abstract][Full Text] [Related]
5. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly.
Andries M; Glintborg D; Kvistborg A; Hagen C; Andersen M
Clin Endocrinol (Oxf); 2008 Mar; 68(3):473-80. PubMed ID: 17941902
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance.
Yamaguchi H; Shimatsu A; Okayama A; Sato T
Endocr J; 2020 Feb; 67(2):201-210. PubMed ID: 31723069
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly.
Bernabéu I; Fajardo C; Marazuela M; Cordido F; Venegas EM; de Pablos-Velasco P; Maroto GP; Olvera MP; de Paz IP; Carvalho D; Romero C; De la Cruz G; Escolá CÁ
Endocrine; 2020 Dec; 70(3):575-583. PubMed ID: 32725444
[TBL] [Abstract][Full Text] [Related]
8. Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naïve to somatostatin-receptor ligands: analysis of three multicenter clinical trials.
Alquraini H; Del Pilar Schneider M; Mirakhur B; Barkan A
Pituitary; 2018 Jun; 21(3):283-289. PubMed ID: 29357081
[TBL] [Abstract][Full Text] [Related]
9. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study.
Puig-Domingo M; Soto A; Venegas E; Vilchez R; Blanco C; Cordido F; Lucas T; Marazuela M; Casany R; Cuatrecasas G; Fajardo C; Gálvez MÁ; Maraver S; Martín T; Romero E; Paja M; Picó A; Bernabeu I; Resmini E;
Endocrinol Nutr; 2016 Oct; 63(8):397-408. PubMed ID: 27448708
[TBL] [Abstract][Full Text] [Related]
10. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
[TBL] [Abstract][Full Text] [Related]
11. High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study.
Giustina A; Mazziotti G; Cannavò S; Castello R; Arnaldi G; Bugari G; Cozzi R; Ferone D; Formenti AM; Gatti E; Grottoli S; Maffei P; Maffezzoni F; Montini M; Terzolo M; Ghigo E
J Clin Endocrinol Metab; 2017 Jul; 102(7):2454-2464. PubMed ID: 28419317
[TBL] [Abstract][Full Text] [Related]
12. COMPARATIVE EFFICACY OF MEDICAL TREATMENT FOR ACROMEGALY: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF INTEGRATED RANDOMIZED TRIALS AND OBSERVATIONAL STUDIES.
Qiao N; He M; Shen M; Zhang Q; Zhang Z; Shou X; Wang Y; Zhao Y; Tritos NA
Endocr Pract; 2020 Apr; 26(4):454-462. PubMed ID: 32045295
[No Abstract] [Full Text] [Related]
13. Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly.
Tutuncu Y; Berker D; Isik S; Ozuguz U; Akbaba G; Kucukler FK; Aydin Y; Guler S
Pituitary; 2012 Sep; 15(3):398-404. PubMed ID: 21863263
[TBL] [Abstract][Full Text] [Related]
14. ACROBAT Edge: Safety and Efficacy of Switching Injected SRLs to Oral Paltusotine in Patients With Acromegaly.
Gadelha MR; Gordon MB; Doknic M; Mezősi E; Tóth M; Randeva H; Marmon T; Jochelson T; Luo R; Monahan M; Madan A; Ferrara-Cook C; Struthers RS; Krasner A
J Clin Endocrinol Metab; 2023 Apr; 108(5):e148-e159. PubMed ID: 36353760
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness and Efficacy of a Novel Combination Regimen in Acromegaly: A Prospective, Randomized Trial.
Bonert V; Mirocha J; Carmichael J; Yuen KCJ; Araki T; Melmed S
J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32754748
[TBL] [Abstract][Full Text] [Related]
16. A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registry.
Salvatori R; Gordon MB; Woodmansee WW; Ioachimescu AG; Carver DW; Mirakhur B; Cox D; Molitch ME
Pituitary; 2017 Dec; 20(6):605-618. PubMed ID: 28741071
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and acceptability of lanreotide Autogel® 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR.
Schopohl J; Strasburger CJ; Caird D; Badenhoop K; Beuschlein F; Droste M; Plöckinger U; Petersenn S;
Exp Clin Endocrinol Diabetes; 2011 Mar; 119(3):156-62. PubMed ID: 21086246
[TBL] [Abstract][Full Text] [Related]
18. Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review.
Cella D; Evans J; Feuilly M; Neggers S; Van Genechten D; Herman J; Khan MS
Adv Ther; 2021 Feb; 38(2):969-993. PubMed ID: 33432541
[TBL] [Abstract][Full Text] [Related]
19. Pasireotide: potential treatment option for McCune-Albright-associated acromegaly.
Ilie MD; Raverot G; Brac de la Perrière A
Eur J Endocrinol; 2024 Jan; 190(1):K17-K20. PubMed ID: 38128124
[TBL] [Abstract][Full Text] [Related]
20. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
Yang LP; Keating GM
Drugs; 2010 Sep; 70(13):1745-69. PubMed ID: 20731479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
